abstract |
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of mineralocorticoid receptors (MR) and pharmaceutical compositions thereof. The compounds of the present invention may be useful for the treatment of various diseases related to the expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and / or diseases related to aldosterone excess. |